| 1. |
- Nyström, Hanna, 1980-, et al.
(författare)
-
Type IV collagen as a tumour marker for colorectal liver metastases.
- 2011
-
Ingår i: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. - : Elsevier BV. - 1532-2157 .- 0748-7983. ; 37:7, s. 611-7
-
Tidskriftsartikel (refereegranskat)abstract
- About 50% of patients with primary colorectal cancer (CRC) will develop liver metastases (CLM). Currently, carcinoembryonic antigen (CEA) is the most common tumour marker for CRC and CLM. However, the sensitivity and specificity of this marker is not optimal, as almost 50% of patients have tumours that do not produce CEA. Therefore there is a need for better markers for CRC and CLM.
|
|
| 2. |
- Lindnér, Per, 1956, et al.
(författare)
-
Extended right-sided liver resection for colorectal liver metastases--impact of percutaneous portal venous embolisation
- 2006
-
Ingår i: European journal of surgical oncology. - 0748-7983. ; 32:3, s. 292-6
-
Tidskriftsartikel (refereegranskat)abstract
- AIM: To compare the outcome after extended right liver lobe resection (ERL) for patients with liver metastases from colorectal cancer with preceding portal vein embolisation (PVE) with a non-PVE-group. METHODS: Nineteen patients underwent ERL (resection of segment 4-8) for colorectal liver metastases after PVE. They were compared with 21 patients that underwent an ERL without embolisation. A comparison was made with 84 patients undergoing right lobe liver resection during the same time period. Survival, post-operative morbidity and mortality were recorded and the volume of the future remnant liver (FRL) was measured with CT. RESULTS: There were major complications in 1/19 patients in the PVE-group and in 6/21 in the non-PVE-group (p=0.04). No post-operative deaths were observed in the PVE-group, compared to three deaths in the non-PVE-group (p=0.09). The median survival in the PVE-group was 32 months, which did not differ from the non-PVE-group. In 21% of the patients that underwent PVE, progression occurred during the time between embolisation and surgery. There was no difference in survival for patients that underwent PVE followed by ERL, compared to patients that underwent standard right lobe liver resection. CONCLUSION: The survival of patients after ERL is comparable with patients that undergo standard right lobe resection and have less liver tumour.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Oman, M, et al.
(författare)
-
Treatment of non-resectable pancreatic cancer with intraperitoneal 5-FU and leucovorin IV.
- 2001
-
Ingår i: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. - : Elsevier BV. - 0748-7983. ; 27:5, s. 477-81
-
Tidskriftsartikel (refereegranskat)abstract
- To explore the feasibility of intraperitoneal (IP) 5-fluorouracil (5-FU) and (IV) leucovorin for patients with advanced pancreatic carcinoma.
|
|
